Latest news

Debiopharm Group™ s’installe dans son “Espace «après-demain»” au sein du quartier de l’innovation de l’EPFL

INC Research and Debiopharm Group ™ announce Strategic Partnership

Continuity as Debiopharm Group™ management moves forward

Debiopharm and Yale announce an exclusive license agreement for the development and commercialization of Debio 1036, a first-in-class inhibitor for…

The Debiopharm Group and Marina Biotech Partner to Develop and Commercialise RNAi-based Therapies for the Treatment of Bladder Cancer

Diagnoplex Closes an Extension of Its Series A Financing with a substantial Investment by Debiopharm Group™

Frost & Sullivan Presents Debiopharm Group™ with “European Biopharmaceuticals Company of the Year Award”

Abionic wins the ‘Prix Debiopharm Valais pour les Sciences de la Vie’ for its innovative biomedical device for diagnostic testing

Inauguration du “Debiopharm Laboratory”: Debiopharm Group équipe la Haute Ecole Spécialisée – SO Valais d’un laboratoire peptidique de pointe